Gene · 1237
Papers2,300
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 2,300
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Role of the chemokine system in liver fibrosis: a narrative review. | Dig Med Res | 2022 | 36339901 | PubTator, text mining | PubMed |
| Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma. | Front Genet | 2022 | 36338983 | PubTator, text mining | PubMed |
| Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment. | Front Oncol | 2022 | 36338771 | PubTator, text mining | PubMed |
| Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis. | Front Surg | 2022 | 36338652 | PubTator, text mining | PubMed |
| Perivascular spaces and their role in neuroinflammation. | Neuron | 2022 | 36327898 | PubTator, text mining | PubMed |
| Construction and analysis of a lncRNA-miRNA-mRNA competing endogenous RNA network from inflamed and normal synovial tissues after anterior cruciate ligament and/or meniscus injuries. | Front Genet | 2022 | 36324509 | PubTator, text mining | PubMed |
| CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer. | BMC Med Genomics | 2022 | 36316684 | PubTator, text mining | PubMed |
| Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma. | Front Genet | 2022 | 36313455 | PubTator, text mining | PubMed |
| Downregulation of FXYD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma. | J Immunol Res | 2022 | 36313180 | PubTator, text mining | PubMed |
A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment. | Front Immunol | 2022 | 36311770 | PubTator, text mining | PubMed |
| Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors. | Front Immunol | 2022 | 36311703 | PubTator, text mining | PubMed |
| ZNF521 Is Correlated with Tumor Immune Cell Infiltration and Act as a Valuable Prognostic Biomarker in Gastric Cancer. | Gastroenterol Res Pract | 2022 | 36311294 | PubTator, text mining | PubMed |
| A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. | J Clin Transl Hepatol | 2022 | 36304510 | PubTator, text mining | PubMed |
| Increased Expression of INHBA Is Correlated With Poor Prognosis and High Immune Infiltrating Level in Breast Cancer. | Front Bioinform | 2022 | 36304286 | PubTator, text mining | PubMed |
| The Inflammasomes Adaptor Protein PYCARD Is a Potential Pyroptosis Biomarker Related to Immune Response and Prognosis in Clear Cell Renal Cell Carcinoma. | Cancers (Basel) | 2022 | 36291776 | PubTator, text mining | PubMed |
| Suppressive Effects of 4-(Phenylsulfanyl) Butan-2-One on CCL-1 Production via Histone Acetylation in Monocytes. | Curr Issues Mol Biol | 2022 | 36286030 | PubTator, text mining | PubMed |
| CXCL2 acts as a prognostic biomarker and associated with immune infiltrates in stomach adenocarcinoma. | Medicine (Baltimore) | 2022 | 36281171 | PubTator, text mining | PubMed |
| Application of mesenchymal stem cell-derived exosomes from different sources in intervertebral disc degeneration. | Front Bioeng Biotechnol | 2022 | 36277386 | PubTator, text mining | PubMed |
| TRAT1 overexpression delays cancer progression and is associated with immune infiltration in lung adenocarcinoma. | Front Oncol | 2022 | 36276113 | PubTator, text mining | PubMed |
| Strategies to overcome DC dysregulation in the tumor microenvironment. | Front Immunol | 2022 | 36275666 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1237/papers?page=25